Figure 2.
Technetium‐99m pyrophosphate (99mTc‐PYP) scintigraphy at baseline (A and B) and 1 year after tafamidis treatment (C and D).
Technetium‐99m pyrophosphate (99mTc‐PYP) scintigraphy at baseline (A and B) and 1 year after tafamidis treatment (C and D).